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OBJECTIVE — Little is known regarding recent changes in glitazone use.
RESEARCHDESIGNANDMETHODS — Interruptedtimeseriesanalysesofnationally
representative ofﬁce-visit data using IMS Health’s National Disease and Therapeutic Index.
RESULTS — From2003through2005,glitazoneuseincreasedsteadily.FromFebruary2005
to January 2007, rosiglitazone use decreased by 16% (95% CI 20 to 11) annually; pioglita-
zone use increased at an annual rate of 14% (9–18). During a period of Food and Drug Admin-
istration (FDA) advisories, rosiglitazone use declined sharply from 0.42 million monthly
treatment visits (February 2007) to 0.13 million monthly visits (May 2008). Pioglitazone use
remained stable, accounting for 5.8 million physician visits (77% of all glitazone use) where a
treatment was used during the ﬁnal 12 months of observation.
CONCLUSIONS — The combined effect of scientiﬁc publications, advisories, and media
exposure was associated with a substantial decrease in rosiglitazone use. Despite a class-level
FDA advisory, pioglitazone use was not similarly affected.
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D
iabetes treatments change and
evolve, and glitazones were rapidly
incorporated into practice, with U.S.
expenditures reaching $4.2 billion in 2007
(1). Even early evidence suggested rare but
serious adverse cardiovascular events with
glitazone use (2). Based on accumulating
evidence (3), in May 2007 the Food and
Drug Administration (FDA) issued an advi-
sory about rosiglitazone’s cardiovascular
risks (4,5), followed by a class-wide advi-
sory in August 2007 and an additional ros-
iglitazone advisory in November 2007 (4).
Emerging scientiﬁc evidence and the
FDAadvisoriesreceivedconsiderableme-
dia coverage, and each of these factors
mayhavebeeninﬂuentialinaffectingpio-
glitazoneandrosiglitazoneuse.Weexam-
ine pioglitazone and rosiglitazone use
based on a nationally representative audit
of ofﬁce-based physicians.
RESEARCH DESIGN AND
METHODS— We used the IMS Na-
tional Disease and Therapeutic Index (NDTI)
to obtain monthly data on oral diabetic thera-
pies from January 2003 to June 2009 (5,6).
Our outcome variable was a treatment visit,
deﬁnedasavisitduringwhichthepatientwas
treated with a glitazone.
EachdrugtherapywithintheNDTIis
linked to a speciﬁc six-digit taxonomic
code capturing information similar to the
ICD-9. We queried this for diagnoses of
diabetes, excluding those aged 35 years
or those with type 1 diabetes. In second-
ary analyses, we examined whether there
was evidence that decreases in glitazone
use following the FDA advisories oc-
curred differentially among individuals at
higher cardiovascular risk.
We used time series regressions to ex-
amine glitazone use from 1) January 2003
through January 2005, prior to most safety
signals; 2) February 2005 through January
2007, during which safety signals began to
emerge; 3) February 2007 through May
2008,whentheFDAcommunicatedmulti-
ple advisories; and 4) June 2008 through
June 2009. We separated the ﬁrst from the
secondperiodbasedonavisualdatainspec-
tion (Fig. 1) and JoinPoint analyses (7). For
eachperiod,wedescribedalevelofuse(av-
erage number of treatment visits during pe-
riod) and a slope (monthly change in the
number of treatment visits). Models in-
cluded a constant, a term indicating study
month,adummyvariableindicatingthepe-
riod, and an interaction term between
month and period. We used autoregressive
integrated moving average (ARIMA) mod-
els to control the autocorrelated variables,
varying the moving average structure of the
error terms accordingly (8).
RESULTS— From January 2003 to
May 2005, the annual growth rate for gli-
tazone treatment visits was 22% (95% CI
19–25) (online appendix [available at
http://care.diabetesjournals.org/cgi/
content/full/dc09-1834/DC1]). At their
maximum, glitazone accounted for 34%
of all treatment visits (11.2 million glita-
zone treatment visits during 2005) for
type 2 diabetes. From February 2007
through May 2008, during the period of
FDA advisories, aggregate glitazone use
decreased at an annual rate of 29% (31
to27),reachinganewlevelof0.72mil-
lion (0.67–0.77) treatment visits per
month during this period (Fig. 1). Use
then reached a plateau, with a statistically
insigniﬁcant decline of 2% (9 to 5) dur-
ing the ﬁnal period of observation.
Both agents grew similarly from Jan-
uary 2003 through January 2005, with
annual growth rates of 32% (95% CI 24–
39%) and 14% (8–20) for rosiglitazone
and pioglitazone, respectively. Trends di-
verged markedly during the period of
FDA advisories, with a 60% annual re-
duction in use of rosiglitazone (64 to
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tazone (17 to 0.3). Following the
FDA advisories, use stabilized with ros-
iglitazone, accounting for 23% of glita-
zone use, totaling 1.8 million (1.4–2.1)
visits from June 2008 to June 2009 as
compared with 5.8 million (5.0–6.5) for
pioglitazone, which accounted for the re-
mainder of glitazone use.
Thepercentageofpatientscodiagnosed
withcongestiveheartfailure,coronaryheart
disease, hypertension, atherosclerosis, or
cerebrovascular disease on rosiglitazone or
pioglitazone remained approximately a
third from 2003 until June 2009, and no
substantialchangeintheagedistributionof
pioglitazone and rosiglitazone users oc-
curred (data not shown).
CONCLUSIONS — We found rapid
increases in glitazone use from their mar-
ket debut until 2005. As scientiﬁc evi-
dence, FDA advisories, and media
coverage of their potential cardiovascular
risksaccrued,therewasasharpdeclinein
rosiglitazoneuse;theinitialdeclinebegan
up to 2 years prior to the May 2007 FDA
advisory. Despite a class-wide advisory in
August 2007, pioglitazone treatment vis-
its did not similarly decline. Consistent
with settings of technology adoption
(9,10),decreasesinrosiglitazoneandpio-
glitazone use occurred nonselectively,
rather than among those at highest car-
diovascular risk (data not shown). These
changes are important because glitazones
were widely adopted into practice follow-
ing their market debut, despite questions
regarding their potential safety.
The substantial difference in market
response to the FDA advisories between
rosiglitazoneandpioglitazoneisnotewor-
thy, and debates continue regarding the
degree to which the cardiovascular risks
that have been best demonstrated with
rosiglitazonereﬂectaclass-effect.Consid-
erable evidence supports the greater
safety of pioglitazone as compared with
rosiglizatone(11,12),andthefactthatde-
clines in rosiglitazone began far prior to
the FDA advisory suggests that clinicians,
to some degree, may have heeded early
safety signals (2). Nevertheless, the con-
tinuing uncertainty regarding the cardio-
vascular risks of these agents, as well as
the degree of within-class heterogeneity
in risk, suggests the importance of the
routine inclusion of cardiovascular end
pointsinstudiesthatareusedtoseekFDA
approval for diabetes therapies (13). The
potentialrisksoftheglitazones,relativeto
other available agents (e.g., sulfonyureas,
biguanides), also suggests their limited
roleasmonotherapyfordiabetesorusein
patients at elevated risk of congestive
heart failure or ischemic heart disease.
Our study has several limitations. We
examined limited outcomes and used
cross-sectional data precluding examin-
ing longitudinal prescribing patterns.
Nevertheless, our ﬁndings suggest a sub-
stantial decrease in the use of rosiglita-
zone by these ofﬁce-based physicians
during the FDA advisories that occurred
between February 2007 and May 2008.
Similarly large reductions in pioglitazone
were not observed, nor did reductions in
glitazone use appear to be concentrated
among the elderly or those otherwise at
highest risk for adverse events from these
therapies.Thepublichealthimpactofthe
changes described is not clear.
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